| Market Cap | ₹87Cr |
| ROE | 35.97% |
| P/E Ratio(TTM) | 18.51 |
| EPS(TTM) | 3.73 |
| P/B Ratio | 1.70 |
| Dividend Yield | 0.00% |
| Industry P/E | 56.37 |
| Book Value | 40.53 |
| Debt to Equity | 0.26 |
| Face Value | 10 |
| Managing Director | Rohit Prakash Srivastava |
| Founded | 2021 |
| NSE Symbol | INVICTA |
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| Dr Lal PathLabs | NA (0.00%) | 45.34 | ||
| Vijaya Diagnostic Centre | NA (0.00%) | 68.60 | ||
| Metropolis Healthcare | NA (0.00%) | 61.06 | ||
| Thyrocare Technologies | NA (0.00%) | 47.33 |